Inherently Multimodal Nanoparticle-Driven Tracking and Real-Time Delineation of Orthotopic Prostate Tumors and Micrometastases

Tracy W. Liu, Thomas D. MacDonald, Cheng S. Jin, Joseph M. Gold, Robert G. Bristow, Brian C. Wilson, and Gang Zheng

Ontario Cancer Institute, Campbell Family Institute for Cancer Research and Techna Institute, UHN, 610 University Avenue, Toronto, ON Canada M5G 2M 9, Department of Medical Biophysics, University of Toronto, 610 University Avenue, Toronto, ON Canada M5G 2M9, Department of Pharmaceutical Sciences, University of Toronto, 144 College Street, Toronto, ON Canada M5S 3M2, and Princess Margaret Cancer Center, UHN, 610 University Avenue, Toronto, ON Canada M5T 2M9.

† Contributed equally to this work (T.W.L. and T.D.M.).

ABSTRACT Prostate cancer is the most common cancer among men and the second cause of male cancer-related deaths. There are currently three critical needs in prostate cancer imaging to personalize cancer treatment: (1) accurate intraprostatic imaging for multiple foci and extracapsular extent; (2) monitoring local and systemic treatment response and predicting recurrence; and (3) more sensitive imaging of occult prostate cancer bone metastases. Recently, our lab developed porphysomes, inherently multimodal, all-organic nanoparticles with flexible and robust radiochemistry. Herein, we validate the first in vivo application of 64Cu-porphysomes in clinically relevant orthotopic prostate and bony metastatic cancer models. We demonstrate clear multimodal delineation of orthotopic tumors on both the macro- and the microscopic scales (using both PET and fluorescence) and sensitively detected small bony metastases (<2 mm). The unique and multifaceted properties of porphysomes offers a promising all-in-one prostate cancer imaging agent for tumor detection and treatment response/recurrence monitoring using both radionuclide- and photonic-based strategies.

KEYWORDS: orthotopic · prostate cancer · porphysomes

There is a consensus among the medical community that the perfunctory use of radical therapies is leading to the widespread overtreatment of biologically indolent prostate cancers. Alternative, nonradical, treatment strategies include active surveillance of indolent cancers and intraprostatic focal therapies (rather than treating the entire gland to preclude or minimize side effects of treatment). At the other end of the spectrum, for advanced stage disease, there is a great need to triage patients with occult micrometastatic disease to better systemic therapies to cure patients that have minimal systemic burden to decrease prostate cancer-related deaths in men. Imaging plays a critical role in all of these strategies. Therefore, improvements in prostate cancer imaging must include the ability to delineate small areas of multifocal disease and micrometastases in an accurate and precise manner. Anatomical imaging modalities such as MRI, ultrasound, and CT are the most common current imaging methods used to assess prostate cancer. Unfortunately, all three have unsatisfactorily low accuracies in detecting clinically significant disease, as cancerous tissue is often indistinguishable from healthy tissues. Therefore, to personalize medicine, clinicians have three critical needs for prostate cancer imaging: (1) accurate intraprostatic imaging at early stages; (2) monitoring treatment response and imaging early recurrence; and (3) imaging of prostate cancer bone micrometastases. An imaging modality that could accurately describe the disease in these three states would give clinicians the...
information necessary to properly classify disease extent and prognosis and plan treatment based on initial and intratreatment response. Notable among the emerging imaging modalities are functional imaging techniques such as fluorescence imaging and positron emission tomography (PET). Optical imaging has received much attention due to its ease of implementation, operational simplicity, low cost, and ability to provide real-time information about surgical margins, thereby extending the surgeon’s vision ensuring complete surgical resection of tumors.\textsuperscript{17–20} PET provides quantitative drug biodistribution, effective treatment planning and monitoring and noninvasive deep tissue (>5 cm) images,\textsuperscript{21} key characteristics beyond what is achievable by fluorescence imaging.\textsuperscript{22,23} With the emergence of multimodal imaging strategies and development of unique contrast agents, the complementary ability of different imaging systems, such as fluorescence and PET/CT, could enable high-resolution and sensitivity in patient assessment.\textsuperscript{24}

**Figure 1.** Schematic diagram of the multimodal properties of \textsuperscript{64}Cu-porphysomes as a result of directly radiolabeling a fraction of the porphyrin–lipid bilayer of preformed photonic porphysomes creating intrinsic multimodal nanoparticles.

Porphyrins are a unique platform for the development of multifunctional imaging agents. Found in nature, porphyrins are exceptionally strong metal ion chelators with inherent photonic properties.\textsuperscript{26} By chelating a positron emitting metal ion such as copper-\textsuperscript{64} (\textsuperscript{64}Cu) with a porphyrin, one can create a highly stable radiotracer.\textsuperscript{29–33} Alas, the paramagnetic nature of copper \textsuperscript{2+} ions quenches the porphyrins natural fluorescence, so multiple porphyrins are necessary to create a multifunctional probe. An elegant solution lies in the use of the porphyrin-based nanoparticles, porphysomes.\textsuperscript{34} We recently demonstrated that \textsuperscript{64}Cu can be directly incorporated into a small fraction of the porphyrin molecules in a porphysome to create a single, simple, all-organic nanostructure that is both PET and fluorescently active (Figure 1).\textsuperscript{35} \textsuperscript{64}Cu-porphysomes, which are self-assembled from a single porphyrin-lipid building block, stand apart from other nanoparticles as they can be radiolabeled directly, without the need for exogenous chelators or other modifications. By including the radionuclide directly into the building blocks, the nanoparticles can be faithfully tracked in vivo while ensuring that the pharmacokinetics and biodistribution are not affected.\textsuperscript{35} By virtue of being composed of a single, biodegradable building block,\textsuperscript{36} \textsuperscript{64}Cu-porphysomes achieve a high level of multifunctionality while being free of the complexity and toxicity plaguing other multifunctional nanoparticles\textsuperscript{37} (i.e., complex multi-component biocompatible nanoparticles (liposomes, polymers), toxic or poorly cleared inorganic-core nanoparticles, etc.). While the unlabeled porphysome scaffold is nontoxic,\textsuperscript{34} toxicity could arise from the application of excessive amounts of radioactivity. However, this is easily avoided by controlling the amount of activity per particle with the very flexible labeling procedure.\textsuperscript{35} These intrinsically multimodal \textsuperscript{64}Cu-porphysomes are well suited for prostate cancer imaging given nonindolent, malignant prostate tissue is twice as vascularized as healthy prostate.\textsuperscript{43} Thus, we expect increased \textsuperscript{64}Cu-porphysome uptake and retention in nonindolent prostate tumors owing to the nanoparticle’s ability to extravasate through malignant vasculature.\textsuperscript{44} Critically, to evaluate \textsuperscript{64}Cu-porphysome, we have used several clinically relevant prostate cancer models; orthotopic models whereby prostate tumor
cells are implanted and grown in the prostate gland itself better mimicking the clinical growth, location, and microenvironment of the disease displayed by patients and a systemic metastatic model representing the spread of prostate cancer to the bone.

Herein, we report a proof-of-principle study evaluating this nanoparticle driven platform for multimodality imaging and discuss the clinical potential of $^{64}$Cu-porphysomes to address the current clinical needs in prostate cancer imaging. $^{64}$Cu-porphysomes accumulate selectively in localized prostate tumors with low nonspecific accumulation in surrounding healthy prostate, allowing for clear tumor delineation. We then show $^{64}$Cu-porphysomes’ ability to sensitively detect small (<2 mm) prostate-derived bony metastases. The $^{64}$Cu-porphysome platform has potential for detecting disease progression, treatment planning, and monitoring treatment response and recurrence. To the best of our knowledge, this is the first report of a multimodal PET and fluorescent nanoparticle delineating prostate tumors and micrometastases.

RESULTS

$^{64}$Cu-Porphysome Uptake in the PC3 Orthotopic Tumor Model.

The tumor uptake of $^{64}$Cu-porphysomes was evaluated in the PC3 orthotopic model at 4 and 24 h postintra-venous injection. Time points beyond two half-lives of $^{64}$Cu were not investigated, as this would require both high radioactivity doses and long scan times to achieve measurable activity. At 4 h, the prostate tumor was not easily delineated in the PET/CT image (Figure 2A) and the radioassay studies demonstrated a tumor %ID/g of only 3.16 ± 0.36 (Figure 2B). The low tumor and high intestinal uptake (5.50 ± 2.09%ID/g) gives a low tumor-to-tissue ratio (0.62 ± 0.18), making it difficult to visualize the tumor at 4 h. In contrast, the tumor is clearly identifiable at 24 h (Figure 2C,D) due to a significant ($p < 0.001$), greater than 2-fold increase in tumor uptake, 6.83 ± 1.08%ID/g (Figure 2B), increasing the tumor-to-gut ratio to 1.53 ± 0.28 (Figure 2D). The retention of $^{64}$Cu-porphysomes within the tumor is evident from the tumor-to-muscle ratio increasing from 5.06 ± 0.49 to 12.7 ± 6.1 from 4 to 24 h (Figure 2D).

Similar to many other nanoparticles, porphysomes are cleared through the hepatobiliary route, resulting in the high accumulation within the liver and spleen.$^{39,45}$ Importantly, no accumulation was observed in the bladder at any time point, which has been the “Achilles heel” of many small molecule radiotracers used in prostate cancer imaging given that the normal tissue signal of the bladder overlays with that of the target tissue signal of the prostate gland. The 24 h time point was chosen as the optimum imaging time, as it provides the highest prostate tumor uptake, delineation, and high tumor-to-background ratio.

$^{64}$Cu-Porphysome Selectivity in Orthotopic Prostate Tumor.

We then tested the selectivity of $^{64}$Cu-porphysomes within the PC3 and 22RV1 orthotopic prostate cancer models. Figure 3 displays representative PET/CT images comparing the PC3 (Figure 3A) and 22RV1 (Figure 3B) models with healthy male mice (Figure 3C) at 24 h post-$^{64}$Cu-porphysome intravenous injection.

$^{64}$Cu-porphysomes clearly delineate the orthotopic tumors, while the non-tumor-bearing mice displayed minimal signal in the prostate region. Encouragingly,
64Cu-porphysomes clearly demarcate not only the larger PC3 tumors, but also 22RV1 tumors that were less than half their size (5 and 2 mm, respectively, as determined by MRI; Figure S1). Clear tumor delineation was also demonstrated by fluorescence imaging (Figure 3F,G): PC3 tumors had approximately 9- and 4-fold higher fluorescence (total signal/area), compared to the normal prostate tissue in both healthy mice and tumor-bearing animals (Figure 3H). The radioassay data confirmed the selectivity of 64Cu-porphysomes for cancerous tissue: PC3 tumor-to-prostate ratio of 5.75 (1.53, with 6.83 (1.08%ID/g and 1.23 (0.202%ID/g, respectively (Figure 3D,E). The findings in the 22RV1 model were similar, with a tumor-to-prostate ratio of 7.24 (2.66 with 4.81 (2.06%ID/g and 0.668 (0.132%ID/g, respectively. At 24 h post-injection, both PC3 and 22RV1 had tumor-to-muscle ratios >12 (Figure S2). A second control group was used to evaluate whether the surgical tumor inoculation procedure affected the accumulation of 64Cu-porphysome in the prostate gland. However, both the untreated control and surgery-only groups had similar 64Cu-porphysome accumulation: 1.45 ± 0.16%ID/g and 1.10 ± 0.50%ID/g (Figure 3F,G). 64Cu-porphysome uptake in tumors for both models was significantly higher (p < 0.05) than healthy prostate tissue in all groups. There was significant uptake in both the spleen and liver in all models, as would be expected for a nanoparticle which is too large to be cleared by the renal system. The tumor selectivity of 64Cu-porphysomes was further demonstrated by fluorescent microscopy of tissue slices, comparing tumor and uninvolved prostate tissue from the orthotopic PC3 and 22RV1 models with healthy prostate from surgery-only mice (Figure 4).

The regions that demonstrated high porphyrin fluorescence corresponded to areas with cancer cell morphology (oversized nuclei, disorganized structure), while uninvolved prostate tissue, characterized by organized glandular structures with small nuclei, showed minimal porphysome fluorescence. There was minimal fluorescence in the surgery-only prostate tissue sections. In summary, the PET/CT images, the biodistribution data, and the in situ fluorescence and fluorescence microscopy all clearly demonstrate the selectivity of 64Cu-porphysomes for malignant tissue in these orthotopic prostate cancer models.

64Cu-Porphysomes for Detection of Metastatic Prostate Tumor. The metastatic Ace-1-YFP-Luc prostate cancer
cell line was used to mimic prostate metastases forming in the bone.\textsuperscript{46} Metastatic involvement was confirmed in four mice by BLI imaging at 14 d post-Ace-1 injection, as illustrated in Figure 5A, and by post-mortem histology. Healthy control animals demonstrate no bioluminescence (Figure S3).\textsuperscript{64}Cu-porphysome uptake was seen in the 3D PET/CT images of the corresponding mice at 24 h post-injection (Figure 5Bi), while the healthy animals showed minimal signal in the lower limbs (Figure 5Bii).\textsuperscript{64}Cu-porphysome accumulation was easily visualized in the lower extremities that were well separated from the high uptake of \textsuperscript{64}Cu-porphysomes in the liver and spleen. The location of \textsuperscript{64}Cu-porphysome accumulation in the PET/CT images (Figure 5Bi) matched the localization of metastases in the histology slices; both demonstrate tumors in the distal femur (Figure 5Bi, blue arrow, and Ci) and proximal tibia (Figure 5Bi, white arrow, and Cii,iii). All four mice with confirmed metastases by BLI imaging and histology all demonstrated \textsuperscript{64}Cu-porphysomes accumulation in either the distal femur, proximal tibia, or both. The development of spinal metastases is often associated with prostate cancer. We also evaluated PET/CT imaging of small metastases within the spinal column (Figure 5D,E), confirmed by BLI and H&E histological analysis (Figure 5A,F) in the lumbar vertebrae. There was no corresponding PET signal within the spine in control animals (Figure 5E).

Based on the H&E histology slides (Figure S4), the metastatic lesions ranged from 0.5 to 1.7 mm along the longest axis. Due to the 1.4 mm resolution of the PET imaging system, individual lesions less than 1.4 mm apart were not resolved within the bone by PET. The uptake of \textsuperscript{64}Cu-porphysomes was measured from the PET images and demonstrated a mean voxel of 6.40 ± 0.91, 3.66 ± 0.30, and 4.11 ± 0.41%ID/g within metastases found in the spine, femur, and tibia, respectively, with a maximum voxel %ID/g of 9.36 ± 0.91, 6.36 ± 0.84, and 7.36 ± 1.28 (Figure S4). Taken together, the BLI images, the PET/CT images and histology all clearly demonstrate the selectivity of \textsuperscript{64}Cu-porphysomes to image micrometastases in these metastatic prostate cancer models.

**DISCUSSION**

One current practice for men presenting with prostate cancer is radical localized treatment, despite the risk and regardless of tumor stage, resulting in significant overtreatment.\textsuperscript{2,3} Screening studies suggest that as many as 48 prostate cancer patients need to be treated in order to save one life.\textsuperscript{2,3} Radical treatments such as brachytherapy, external beam radiation therapy, and surgery remove or destroy the entire prostate gland in order to ensure complete eradication of the cancer. This approach is often successful at removing disease but drastically decreases patients’ quality of life.\textsuperscript{47,48} The associated morbidities of radical therapies, primarily impotence and incontinence, are devastating and occur at a high frequency.\textsuperscript{47,48} These side effects stem from damage or wholesale removal of neurovascular bundles necessary for normal function. The multifunctional nature of \textsuperscript{64}Cu-porphysomes may provide a means to avoid these side effects by acting as a PET treatment planning tool, delineating intraglandular foci of prostate tumor involvement, and translating that onto the surgical table or radiotherapy planning through fluorescence image guidance. Beneficially,
both of these capabilities are derived from a single functional building block, preserving simplicity and making $^{64}\text{Cu}$-porphysomes more easily translatable.

Here, we mimic localized primary cancer development and its microenvironment using orthotopic prostate cancer models (PC3 and 22RV1). Because

Figure 5. Prostate metastases imaging. (A) Representative bioluminescent images confirming the presence of bony metastases in the supine (i) and prone (ii) positions. (B) (i) Corresponding 3D MicroPET/CT images (blue arrow, distal femur metastases; white arrow, proximal tibia metastases) and (ii) 3D MicroPET/CT image of a healthy mouse. (C) Corresponding histology (H&E) of lower extremities confirming Ace-1 metastases in the (i) distal femur and (ii, iii) proximal tibia. Representative MicroPET/CT images of (i) axial, (ii) coronal, and (iii) sagittal single slices in (D) Ace-1 metastatic and (E) control animals 24 h post-i.v. injection of 500 $\mu$Ci $^{64}\text{Cu}$-porphysomes: inset shows zoomed views of a metastatic lesion. (F) Corresponding histology confirming Ace-1 metastases in the spinal column at 1 x (i) and 4 x (ii) magnification. T, metastases; BM, bone marrow; BC, cortex.
Orthotopic tumors are located as they would be clinically, orthotopic models are superior to xenografts for imaging evaluation, as they are not situated in areas of artificially low background signal and so better represent clinical presentation. Similar to other nanoparticles, $^{64}$Cu-porphysomes are cleared through the hepatobiliary system, producing minimal background in the bladder and peri-prostatic tissues and allowing clear visualization of the tumor. PET/CT imaging showed that $^{64}$Cu-porphysomes delineated hypoxic orthotopic tumors less than 2 mm in size (Figures 2, 3, and S1). In situ fluorescence imaging after opening the peritoneal cavity clearly distinguished prostate tumors from the male reproductive organs (healthy prostate, seminal vesicles, and testes), all of which showed minimal fluorescence (Figure 3). Porphysome accumulation was heterogeneous in tumor tissue (seen in both PET/CT and fluorescence), possibly due to high interstitial pressures and the natural heterogeneity of the tumor microenvironment. The exact mechanism of $^{64}$Cu-porphysome uptake into cancer is not well understood and is the basis of ongoing studies. It is possible that nanoparticle extravasation drives the tumor accumulation, while the cell penetration capability of the pyropheophorbide-$\alpha$.49,50 moieties drives the nanoparticle dissociation and cellular uptake. However, this “ringing” effect could be advantageous as it causes the highest uptake to be in the periphery of the tumor, giving a clear indication of the tumor boundaries. $^{64}$Cu-porphysomes are able to discriminate between tumor and healthy tissues using both PET/CT and fluorescence imaging modalities.

There are also a number of focal modalities currently under investigation including image-guided focal photothermal therapy, photodynamic therapy, high intensity focused ultrasound ablation, focal brachytherapy, image-guided radiotherapy, and focal cryotherapy.2 Focal therapies have demonstrated their effectiveness to treat prostate cancer, from indolent to aggressive, with minimal side effects.3 While attractive due to their low side effects, focal therapies are currently constrained by inadequate tools for accurate intraprostatic imaging. For planning proper disease management, clinicians require a means that accurately depicts the extent of cancer within a diseased prostate. While MRI and trans-rectal ultrasound currently have extensive use in the clinic, they are hampered by limitations such as low sensitivity (particularly for small lesions), low specificity, and irreproducibility.1-16 The PET/CT imaging capability of $^{64}$Cu-porphysomes may provide a more accurate picture of tumor involvement within the prostate providing a potential effective treatment planning tool. Treatment planning with $^{64}$Cu-porphysome PET/CT imaging not only provides a full picture of the prostate but also is noninvasive and would avert the need for inconvenient, inaccurate, and painful repeated biopsies.11,51 Additionally, the fluorescence capability of $^{64}$Cu-porphysomes and its prostate tumor selectivity provides a means to guide and monitor the efficacy of focal treatment in real time ensuring complete eradication of compromised tissue. Although there is considerable uptake in surrounding nonreproductive tissues (i.e., intestines, Figure 3), in the clinical setting, the field of view for intraoperative imaging19,52 can be limited to the reproductive organs, where the specificity for tumor over reproductive tissue is the critical parameter.

Assessing a patient’s response to treatment is a critical part of tailoring a treatment plan to their needs. Currently there is no method for monitoring response in real-time during a treatment procedure. Fluorescence imaging is an attractive modality for real-time intraoperative monitoring of treatment response as it is highly sensitive and easily implemented. Using orthotopic prostate cancer models, we demonstrated the ability of fluorescent imaging to macroscopically discriminate between diseased and healthy tissue (Figure 3F-H). On the microscopic scale, fluorescence imaging of prostate and tumor tissue histology slices also demonstrated clear separation between tissue types (Figure 4). Porphysome fluorescence only accumulated in malignant cells, confirmed by H&E staining, whereas healthy glandular prostate tissue demonstrated little to no fluorescence. The capability to visually identify malignant cells microscopically using $^{64}$Cu-porphysomes could make surgical procedures more successful as surgeons could monitor treatment response in real time, ensuring that the surgical bed is free of any residual tumor cells. This selectivity and the ability to directly visualize diseased tissue with fluorescence may give surgeons the information needed to make nonradical or nerve sparing surgeries more viable.

Currently, the recurrence rate for prostate cancer is as high as 30%.3 Although, PSA is a valuable biochemical tool for monitoring recurrence after radical therapy,54 this assay does not give any information with regards to the progression or localization of disease. Patients with rising levels of PSA are again faced in the same unpleasant predicament when prostate cancer was first diagnosed suffering through painful biopsies and the uncertainty of poorly defined disease. There is currently no consensus on effective strategies to monitor and characterize recurrence.55 Furthermore, the translation of focal therapies into the clinic is constrained by our lack of tools to accurately detect recurrence as healthy prostate tissue spared by focal therapies can confound the PSA assay. The ability of $^{64}$Cu-porphysomes to detect prostate tumors less than 2 mm in size by PET/CT (Figure 3 and S1) may present a viable option for identifying tumor foci and detecting the early stages of recurrence noninvasively. The added information demonstrating not only the presence but also the localization of the recurrent...
tumor may provide clinicians with more information allowing them to better decide upon a treatment regime while giving them the tools needed to bring focal therapies to the forefront of patient care.

Castrate-resistant metastatic spread is associated with death within 18–36 months. Currently, there is no ideal strategy for detecting prostate cancer metastases, the primary cause of morbidity and mortality in these patients. A critical clinical need in prostate cancer imaging is the detection of occult metastatic involvement such that systemic agents can be given earlier in the disease spectrum for a more curative approach. Here, we have demonstrated that ⁶⁴Cu-porphysomes are able to detect >2 mm metastases in the bones of the lower extremities and spinal column in our Ace-1 metastatic cancer model (Figures 5 and S4). Metastases were clearly visualized with PET/CT and confirmed with histological staining. Detection of small metastases has proven difficult for contemporary bone scans which have a detection limit of approximately 1 cm.⁵¹–⁶³ Detecting the metastatic spread to lymph nodes is also of particular interest. We are pursuing the potential of using ⁶⁴Cu-porphysomes to detect and assess the metastatic involvement of the lymphatic system supported by promising preliminary data of ⁶⁴Cu-porphysome PET/CT signals (Figure S5). An imaging study including fluorescence-guided surgical resection and histopathological examination of lymph nodes is underway. The dual PET and optical imaging capabilities of ⁶⁴Cu-porphysomes may be a promising tool for lymph node management as it allows for the noninvasive detection of cancer positive lymph nodes and has application for image-guided assistance intraoperatively. The whole-body imaging capability of PET/CT, combined with the sensitivity of ⁶⁴Cu-porphysomes to detect small metastatic lesions, 2 mm or smaller, potentially provides a novel and potent means to detect micrometastases, localize metastatic spread, and to monitor local or systemic treatment responses.

These preliminary findings are extremely encouraging but there are limitations to address and more capabilities to explore (Figure 6). ⁶⁴Cu-porphysomes rely on passive targeting, a phenomenon whose clinical relevance is a point of contention as it does not allow uniform delivery of nanoparticles to all regions of tumors in sufficient quantities. However, as a PEG-coated nanoparticle, the porphysome platform can easily be functionalized with targeting ligands, for targets such as PSMA, EpCAM, or VEGFR. This functionalization may provide a means to better stratify patients based upon molecular markers, thus personalizing cancer care. Targeting or modifying to PEG shell may also provide a means to reduce ⁶⁴Cu-porphysomes’ high liver and spleen accumulation, thereby improving pharmacokinetics and tumor uptake. Targeted porphysome studies are currently underway. By customizing the porphysome building blocks with a range of porphyrinoids, adding PDT and PTT (free-base Pyro or bacteriochlorophyll-a), radio-(immuno)therapy (⁶⁰Cu-porphyrin or ¹⁷⁷Lu-texaphyrin),
or MRI (Mn-porphyrin or Gd-texaphyrin) capabilities to porphysomes is easily done. This intrinsic multimodality and flexibility of the porphysome platform lends itself to a broad array of future applications.

CONCLUSIONS

We believe that the porphysome platform has the potential to address several unmet clinical needs in prostate cancer imaging and treatment. The plethora of therapeutic potentials of porphysomes will be enriched by the multimodal imaging properties of $^{64}$Cu-porphysomes enabling treatment planning, image-guided therapy, and follow-up monitoring in prostate cancer patients. In conclusion, we have validated the in vivo sensitivity and selectivity of $^{64}$Cu-porphysomes in a number of clinically relevant prostate cancer models using PET and fluorescence imaging. The unique combination of properties of porphysomes offers a promising all-in-one agent that spans tumor detection, treatment, interventional guidance, treatment response assessment, and monitoring of recurrence, using both radionuclide- and photonic-based strategies.

MATERIALS AND METHODS

Formation of Porphysomes. Porphysomes were synthesized using a previously reported protocol34 and comprise 65 mol % pyropheophorbide-$\alpha$-lipid, 30 mol % cholesterol oleate, and 5 mol % DSPE-PEG2000. The nanoparticle size was determined by dynamic light scattering (DLS, Malvern Instruments, Malvern, U.K.) and the concentration by UV/vis spectrophotometry (Varian Inc., Palo Alto, CA). The size (z-average) was between 120 and 130 nm with a PDI of <0.2 (Figure S6).

Radiolabeling. $^{64}$Cu(OAc)$_2$ was obtained from Université de Sherbrooke, QC, Canada and $^{64}$CuCl$_2$ was obtained from Washington University, MO, U.S.A. Porphysomes in PBS were diluted 1:1 with 0.1 M NH$_4$OAC (pH 5.5), before adding a small volume of aqueous $^{64}$CuCl$_2$ ($X = OAC, Cl$) solution and incubating at 60 °C for 30 min. Radiochemical purity and yield were assessed on a radio-UPLC (Waters, Milford, MA, U.S.A.) equipped with a UV/vis module (monitoring 254 nm and 410 nm), eSatin radiation detector, and ELSD module using a size exclusion column (pore size 100 nm, mobile phase H$_2$O). $^{64}$Cu-porphysomes elute from the size-exclusion column early, while any unchelated $^{64}$CuX$_2$ would elute later with the buffer salts and is easily identified in the ELSD channel. The labeled solution was then diluted with PBS to the desired concentration for injection.

Animal Studies. All animal studies were carried out under institutional approval (Ontario Cancer Institute, UHN, Toronto, Canada).

Orthotopic Prostate Tumor Model. Adult male mice (athymic nude, Charles River, 7–8 weeks, 20–25 g average weight) were placed under general anesthesia with 2% isoflurane in oxygen at 2L/min) at 4 or 24 h post-injection, with the images integrated over 10 or 40 min, respectively, followed immediately by CT imaging.

Fluorescence Imaging of Orthotopic Prostate Tumor Models. Immediately after PET/CT imaging at 24 h post- $^{64}$Cu-porphysome injection, animals were euthanized by cervical dislocation, and fluorescence imaging was performed in situ after opening the peritoneal cavity (Maestro: Caliper Life Sciences, MA, U.S.A.) with 680 nm excitation and ≥700 nm detection (autoexposure integration time). Unfortunately, due to the deep-seated nature of orthotopic prostate tumors, in vivo fluorescence imaging was unable to detect tumor fluorescence transdermally. Monochrome images were also taken to aid in locating the fluorescence signals. Regions of interest (ROI) were drawn on the monochrome images in which the seminar vesicles, testes accumulation in the selected tissues. Comparison of the surgery-only controls with the orthotopic tumor-bearing animals was made on the basis of the total fluorescence signals normalized by exposure time and ROI area (total fluorescent signal/area) using a Student t test with a level of significance set at $p < 0.05$. Comparison between different organs in the tumor-bearing animals was made using a paired Student t test with a level of significance set at $p < 0.05$.

Biodistribution. The $^{64}$Cu-porphysome biodistribution was determined using the orthotopic PC3 model. At 4 (n = 4) or 24 h (n = 4) following tail vein injection of $^{64}$Cu-porphysome solution (100–150 μL, 0.43–0.62 mCi, 150–200 nmol pyro-lipid), the mice were imaged under anesthesia (2% isoflurane in oxygen at 2L/min) at 4 or 24 h post-injection, with the images integrated over 10 or 40 min, respectively, followed immediately by CT imaging.

PET/CT Scanning. PET imaging was carried out on a small-animal MicroPET system (Focus 220: Siemens, Munich, Germany). CT imaging was conducted on a microCT system (Locus Ultra: GE Healthcare, U.K.). After tail vein injection of $^{64}$Cu-porphysome solution (100–150 μL, 0.43–0.62 mCi, 150–200 nmol pyro-lipid), the mice were imaged after anesthetia (2% isoflurane in oxygen at 2L/min) at 4 or 24 h post-injection, with the images integrated over 10 or 40 min, respectively, followed immediately by CT imaging.

PET/CT Scanning. PET imaging was carried out on a small-animal MicroPET system (Focus 220: Siemens, Munich, Germany). CT imaging was conducted on a microCT system (Locus Ultra: GE Healthcare, U.K.). After tail vein injection of $^{64}$Cu-porphysome solution (100–150 μL, 0.43–0.62 mCi, 150–200 nmol pyro-lipid), the mice were imaged after anesthetia (2% isoflurane in oxygen at 2L/min) at 4 or 24 h post-injection, with the images integrated over 10 or 40 min, respectively, followed immediately by CT imaging.

PET/CT Scanning. PET imaging was carried out on a small-animal MicroPET system (Focus 220: Siemens, Munich, Germany). CT imaging was conducted on a microCT system (Locus Ultra: GE Healthcare, U.K.). After tail vein injection of $^{64}$Cu-porphysome solution (100–150 μL, 0.43–0.62 mCi, 150–200 nmol pyro-lipid), the mice were imaged after anesthetia (2% isoflurane in oxygen at 2L/min) at 4 or 24 h post-injection, with the images integrated over 10 or 40 min, respectively, followed immediately by CT imaging.

PET/CT Scanning. PET imaging was carried out on a small-animal MicroPET system (Focus 220: Siemens, Munich, Germany). CT imaging was conducted on a microCT system (Locus Ultra: GE Healthcare, U.K.). After tail vein injection of $^{64}$Cu-porphysome solution (100–150 μL, 0.43–0.62 mCi, 150–200 nmol pyro-lipid), the mice were imaged after anesthetia (2% isoflurane in oxygen at 2L/min) at 4 or 24 h post-injection, with the images integrated over 10 or 40 min, respectively, followed immediately by CT imaging.

PET/CT Scanning. PET imaging was carried out on a small-animal MicroPET system (Focus 220: Siemens, Munich, Germany). CT imaging was conducted on a microCT system (Locus Ultra: GE Healthcare, U.K.). After tail vein injection of $^{64}$Cu-porphysome solution (100–150 μL, 0.43–0.62 mCi, 150–200 nmol pyro-lipid), the mice were imaged after anesthetia (2% isoflurane in oxygen at 2L/min) at 4 or 24 h post-injection, with the images integrated over 10 or 40 min, respectively, followed immediately by CT imaging.

PET/CT Scanning. PET imaging was carried out on a small-animal MicroPET system (Focus 220: Siemens, Munich, Germany). CT imaging was conducted on a microCT system (Locus Ultra: GE Healthcare, U.K.). After tail vein injection of $^{64}$Cu-porphysome solution (100–150 μL, 0.43–0.62 mCi, 150–200 nmol pyro-lipid), the mice were imaged after anesthetia (2% isoflurane in oxygen at 2L/min) at 4 or 24 h post-injection, with the images integrated over 10 or 40 min, respectively, followed immediately by CT imaging.

PET/CT Scanning. PET imaging was carried out on a small-animal MicroPET system (Focus 220: Siemens, Munich, Germany). CT imaging was conducted on a microCT system (Locus Ultra: GE Healthcare, U.K.). After tail vein injection of $^{64}$Cu-porphysome solution (100–150 μL, 0.43–0.62 mCi, 150–200 nmol pyro-lipid), the mice were imaged after anesthetia (2% isoflurane in oxygen at 2L/min) at 4 or 24 h post-injection, with the images integrated over 10 or 40 min, respectively, followed immediately by CT imaging.

PET/CT Scanning. PET imaging was carried out on a small-animal MicroPET system (Focus 220: Siemens, Munich, Germany). CT imaging was conducted on a microCT system (Locus Ultra: GE Healthcare, U.K.). After tail vein injection of $^{64}$Cu-porphysome solution (100–150 μL, 0.43–0.62 mCi, 150–200 nmol pyro-lipid), the mice were imaged after anesthetia (2% isoflurane in oxygen at 2L/min) at 4 or 24 h post-injection, with the images integrated over 10 or 40 min, respectively, followed immediately by CT imaging.
orthotopic tumor (n = 3), surgery-only controls (n = 5), and non-tumor-bearing/nonsurgical controls (n = 3). At 24 h post-tail-vein injection of 64Cu-porphysome solution (100–150 μL, 16–23 MBq, 150–200 nmol pyro-lipid), the mice were euthanized and organs excised as above. The tissues examined also included prostate tumor and healthy prostate in addition to the above organs.

**Fluorescence Microscopy and Histology.** A single tumor and healthy prostate sample was removed from each of the orthotopic animals (PC3 (n = 8) and 22RV1 (n = 3) of both tumor and healthy prostate) and control animals (surgery-only control (n = 5), non-tumor-bearing/nonsurgical control (n = 3) of prostate). All these samples were placed in OCT media, allowed to radioactively decay at –80 °C for 10 half-lives (5 days) and then cryosectioned (six sequential 10 μm sections). Frozen tissue slices (10 μm) were immersed in PBS for 5 min, dried, and then the nuclei were stained using 10 μL of mounting solution with DAPI, 406-diamidino-2-phenylindole (Vector Laboratories Inc., CA, U.S.A.). The sections were coverslipped and imaged on a wide-field fluorescence microscope (BX50, Olympus Corporation, PA, U.S.A.) with excitation at 410 ± 70 nm and detection at 685 ± 40 nm. Adjacent sections were H&E stained to confirm tumor. In the Ace-1 metastatic model, the spine, right and left femurs, and tibias were excised and fixed in 10% buffered formalin for one week to allow radioactive decay. The samples were then decalified using ethylenediaminetetraacetic acid (EDTA, Sigma Aldrich, MO, U.S.A) for 2 weeks, sectioned (10 μm), and H&E stained to confirm the presence of metastatic lesions within the bone.

**Conflict of Interest:** The authors declare no competing financial interest.

**Acknowledgment.** We would like to thank Drs. Ming Tsao and Margarete Akens for assistance with histopathology analysis; Dr. Thomas Rosol for kindly providing the Ace-1 YFP-Luc cells; Dr. Warren Foltz for assistance with MR imaging; Dr. Carla Coakley for providing the 22RV1 model; and Dr. David Ja and Margarete Akens for assistance with histopathology analysis.

**Supporting Information Available:** Supplemental figures are provided. This material is available free of charge via the internet at http://pubs.acs.org.
69. Jin, C. S.; Lovell, J. F.; Chen, J.; Zheng, G. Ablation of Hypoxic Tumors with Dose-Equivalent Photothermal, but Not Photodynamic Therapy Using a Nanostructured Porphyrin Assembly. *ACS Nano* 2013, 7, 2541–2550.

70. Liu, T. W.; Chen, J.; Burgess, L.; Cao, W.; Shi, J.; Wilson, B. C.; Zheng, G. Multimodal Bacteriochlorophyll Theranostic Agent. *Theranostics* 2011, 1, 354–362.